NOV 17, 202662 MINS READ
Croscarmellose sodium is fundamentally a cross-linked polymer of carboxymethylcellulose sodium, wherein the cellulose backbone undergoes chemical modification through carboxymethylation followed by controlled cross-linking 378. The base structure originates from cellulose, a linear polysaccharide composed of β(1→4)-linked D-glucose units. During synthesis, hydroxyl groups on the anhydroglucose units are partially substituted with carboxymethyl groups (-CH₂-COONa), introducing anionic character and water solubility to the polymer chain 2.
The defining structural feature distinguishing croscarmellose sodium from its non-cross-linked precursor is the introduction of covalent bridges between polymer chains. This cross-linking process typically employs bifunctional reagents such as propylene glycol or epichlorohydrin under controlled pH conditions (pH 1.0–3.0) 2. The cross-linking density—defined as the number of cross-link points per polymer chain—critically determines the swelling capacity, mechanical strength, and disintegration kinetics of the final material. Patent literature indicates that optimal cross-linking is achieved when the reaction is conducted in aqueous or aqueous-alcoholic media, with subsequent purification steps to remove unreacted cross-linking agents and soluble oligomers 2.
The chemical formula of croscarmellose sodium cannot be represented by a single molecular formula due to its polymeric and cross-linked nature. Instead, it is characterized by:
Analytical techniques such as Fourier-transform infrared spectroscopy (FTIR), nuclear magnetic resonance (NMR), and X-ray diffraction (XRD) are employed to characterize the degree of substitution, cross-linking density, and crystallinity of croscarmellose sodium batches. Compliance with pharmacopeial standards (e.g., Chinese Pharmacopoeia 2010 edition, USP, EP) requires strict control of these structural parameters to ensure batch-to-batch consistency and functional performance 2.
The preparation of croscarmellose sodium involves a multi-step synthetic pathway that integrates carboxymethylation, cross-linking, and purification stages. A representative synthesis protocol, as disclosed in patent literature, comprises the following key steps 2:
Native cellulose is treated with sodium hydroxide (NaOH) to generate alkali cellulose, which subsequently reacts with monochloroacetic acid (ClCH₂COOH) or its sodium salt. This etherification reaction introduces carboxymethyl groups onto the cellulose backbone. Critical process parameters include:
The carboxymethylcellulose sodium intermediate is dispersed in a solvent (water or aqueous ethanol), and the pH is adjusted to 1.0–3.0 using hydrochloric acid or citric acid 2. A cross-linking agent, such as propylene glycol, is then added. The acidic pH protonates carboxylate groups, reducing electrostatic repulsion and facilitating inter-chain proximity for cross-linking. Key parameters include:
Post-reaction, the mixture is neutralized to pH 6.5–7.5 using sodium hydroxide or sodium carbonate, precipitating the cross-linked polymer. The product is washed extensively with water or aqueous ethanol to remove residual cross-linking agents, salts, and soluble oligomers 2. Final drying is conducted at 60–80°C under vacuum or in a fluidized bed dryer to achieve moisture content below 10% (w/w), ensuring stability and flowability.
The synthesized croscarmellose sodium must meet stringent pharmacopeial specifications, including:
Patent CN104447314A emphasizes that products prepared via this optimized route exhibit disintegration performance equivalent to imported reference standards (e.g., Ac-Di-Sol®), validating the method's industrial applicability 2.
Croscarmellose sodium functions primarily as a superdisintegrant in oral solid dosage forms, facilitating rapid tablet or capsule breakdown upon contact with aqueous media 134568. Its mechanism of action is multifaceted, involving physical swelling, wicking, and deformation recovery:
Upon exposure to water or gastrointestinal fluids, croscarmellose sodium rapidly absorbs liquid (up to 4–8 times its weight), causing volumetric expansion 8. The cross-linked network prevents complete dissolution, instead generating internal hydrostatic pressure that disrupts the tablet matrix. This swelling is pH-dependent: at gastric pH (1–3), carboxylate groups are partially protonated, reducing electrostatic repulsion and limiting swelling; at intestinal pH (6–7), full ionization maximizes swelling and disintegration force 37.
The fibrous, porous structure of croscarmellose sodium particles creates capillary channels that draw aqueous media into the tablet core via capillary action. This wicking effect accelerates liquid penetration, particularly in hydrophobic formulations, enhancing the dissolution rate of poorly water-soluble drugs 8.
During tablet compression, croscarmellose sodium particles undergo elastic deformation. Upon hydration, these particles recover their original shape, exerting mechanical stress on the tablet matrix and promoting fragmentation 37.
Patent and formulation studies provide quantitative benchmarks for croscarmellose sodium efficacy:
Croscarmellose sodium demonstrates superior performance compared to other disintegrants such as sodium starch glycolate or non-cross-linked carboxymethylcellulose sodium. Its cross-linked structure provides:
The incorporation of croscarmellose sodium into pharmaceutical formulations requires careful consideration of drug properties, excipient interactions, and manufacturing processes. Patent literature provides detailed case studies illustrating best practices 1456.
A composition comprising S-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate (a hydrophobic, water-unstable CETP inhibitor) and croscarmellose sodium was developed to address stability and bioavailability challenges 1456. Key formulation strategies included:
This formulation achieved >85% dissolution within 30 minutes and maintained chemical stability (>95% API assay) for 24 months at 25°C/60% RH 156.
A pharmaceutical composition comprising 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid (or its sodium salt) and croscarmellose sodium was developed to enhance chemical stability 37. The formulation leveraged croscarmellose sodium's dual role as disintegrant and stabilizing agent:
An oral compacted composition comprising entacapone or nitecapone and croscarmellose sodium (10–14% w/w) was developed to maximize dissolution rate 8. Key findings included:
Based on patent and literature data, the following guidelines are recommended for incorporating croscarmellose sodium into immediate-release tablets:
Croscarmellose sodium's versatility as a pharmaceutical excipient extends across diverse therapeutic areas, with documented applications in cardiovascular, metabolic, neurological, and anti-infective drug formulations.
Croscarmellose sodium is extensively used in formulations targeting dyslipidemia and atherosclerosis. The CETP inhibitor formulations described in patents WO2012059447A1, EP2635273A1, and AU2011322651B2 exemplify its application in managing cardiovascular risk 1456. These formulations address the challenge of delivering hydrophobic, chemically unstable APIs by embedding them in a hygroscopic polymer matrix that simultaneously protects against degradation and enhances dissolution. Clinical implications include improved bioavailability (area under the curve increased by 30–50% compared to non-optimized formulations) and reduced inter-subject variability 156.
For researchers developing next-generation lipid-modifying agents, the following considerations are critical:
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| F. HOFFMANN-LA ROCHE AG | Oral solid dosage forms for hydrophobic and water-unstable cardiovascular drugs requiring enhanced bioavailability and chemical protection in immediate-release tablet formulations. | CETP Inhibitor Tablet Formulation | Croscarmellose sodium (5-7% w/w) combined with hygroscopic polymers provides rapid disintegration within 30-120 seconds and achieves >85% dissolution within 30 minutes while maintaining chemical stability (>95% API assay) for 24 months at 25°C/60% RH. |
| LUZHOU NORTH CHEMICAL INDUSTRY CO. LTD. | Pharmaceutical excipient manufacturing for use as superdisintegrant in immediate-release tablets requiring rapid disintegration and dissolution enhancement across diverse therapeutic categories. | Croscarmellose Sodium (Pharmaceutical Excipient) | Cross-linked carboxymethylcellulose sodium prepared via propylene glycol cross-linking at pH 1.0-3.0 exhibits swelling capacity of 400-800% and meets Chinese Pharmacopoeia 2010 standards with disintegration performance equivalent to imported reference standards. |
| KOWA COMPANY LTD | Oral solid dosage forms containing acid-labile active pharmaceutical ingredients requiring dual functionality of chemical stabilization and rapid disintegration in immediate-release formulations. | 2,2-Dichloro-12-(4-chlorophenyl)-dodecanoic Acid Stabilized Formulation | Croscarmellose sodium at API to excipient ratio of 2:1 to 1:15 (w/w) functions as both disintegrant and stabilizing agent, maintaining low-moisture microenvironment to reduce hydrolytic degradation while ensuring rapid tablet disintegration. |
| ORION CORPORATION | Parkinson's disease treatment formulations requiring maximum dissolution rate enhancement for catechol derivative drugs in immediate-release oral compacted compositions with robust manufacturing performance. | Entacapone/Nitecapone Tablet Formulation | Croscarmellose sodium at 10-14% w/w concentration increases dissolution rate from 70% to >90% at 30 minutes for entacapone tablets, demonstrating superior performance compared to sodium starch glycolate and low-substituted hydroxypropyl cellulose. |